Biologic Drug Product Outsourcing

In Q4 2019, ISR asked 163 outsourcers of biologic drug product about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated to preferred providers (37%), followed by strategic partnerships (33%). To learn more, follow the link to the Biologic Drug Product CMO Quality Benchmarking report preview.